Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding

Protein Science

Volumn 19, Issue 12, 2010, Pages 2267-2278

  Kaar, Joel L ^a,c   Basse, Nicolas ^b   Joerger, Andreas C ^a,b   Stephens, Elaine ^b   Rutherford, Trevor J ^b   Fersht, Alan R ^a,b  

^a MRC CENTRE FOR PROTEIN ENGINEERING   (United Kingdom)

^b MRC LABORATORY OF MOLECULAR BIOLOGY   (United Kingdom)

^c UCB 450   (United States)

Author keywords

Alkylation; Binding; DNA; p53; Protein; Stability

Indexed keywords

CYSTEINE; PROTEIN P53; TRANSCRIPTION FACTOR;

ALKYLATION; ARTICLE; CELL ACTIVITY; COVALENT BOND; DNA BINDING; MASS SPECTROMETRY; MELTING POINT; MUTANT; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN STRUCTURE; SURFACE PROPERTY; TRANSCRIPTION INITIATION; WILD TYPE;

ALKYLATION; CYSTEINE; DNA; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; PROTEIN BINDING; PROTEIN STABILITY; TUMOR SUPPRESSOR PROTEIN P53;

EID: 78649658937     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.507     Document Type: Article

References (38)

1. Bullock AN, Henckel J, DeDecker BS, Johnson CM, Nikolova PV, Proctor MR, Lane DP, Fersht AR (1997) Thermodynamic stability of wild-type and mutant p53 core domain. Proc Natl Acad Sci USA 94:14338-14342. (Pubitemid 28041374)
2. Bullock AN, Henckel J, Fersht AR (2000) Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy. Oncogene 19:1245-1256.
3. Joerger AC, Fersht AR (2007) Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene 26:2226-2242.
4. Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77:557-582.
5. Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9:862-873.
6. Joerger AC, Fersht AR (2010) The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2:a000919.
7. Selivanova G (2010) Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20:46-56.
8. Wiman KG Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Oncogene 29:4245-4252.
9. Friedler A, Hansson LO, Veprintsev DB, Freund SM, Rippin TM, Nikolova PV, Proctor MR, Rudiger S, Fersht AR (2002) A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc Natl Acad Sci USA 99:937-942.
10. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci USA 105:10360-10365.
11. Issaeva N, Friedler A, Bozko P, Wiman KG, Fersht AR, Selivanova G (2003) Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc Natl Acad Sci USA 100:13303-13307.
12. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8:282-288.
13. Bykov VJ, Issaeva N, Zache N, Shilov A, Hultcrantz M, Bergman J, Selivanova G, Wiman KG (2005) Reactivation of mutant p53 and induction of apoptosis in human tumor cells bymaleimide analogs. J Biol Chem 280:30384-30391.
14. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507-2510.
15. North S, Pluquet O, Maurici D, El-Ghissassi F, Hainaut P (2002) Restoration of wild-type conformation and activity of a temperature-sensitive mutant of p53 (p53(V272M)) by the cytoprotective aminothiol WR1065 in the esophageal cancer cell line TE-1.Mol Carcinog 33:181-188.
16. Zache N, Lambert JM, Wiman KG, Bykov VJ (2008) PRIMA-1MET inhibits growth of mouse tumors carrying mutant p53. Cell Oncol 30:411-418.
17. Lambert JM, Gorzov P, Veprintsev DB, SoderqvistM, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15:376-388.
18. Kim DH, Kim EH, Na HK, Sun Y, Surh YJ (2010) 15-Deoxy-delta(12,14)- prostaglandin J(2) stabilizes, but functionally inactivates p53 by binding to the cysteine 277 residue. Oncogene 29:2560-2576.
19. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR (2010) Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem Biol 17:46-56.
20. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci USA 103: 15056-15061.
21. Rodriguez-Martinez JA, Sola RJ, Castillo B, Cintron-Colon HR, Rivera-Rivera I, Barletta G, Griebenow K (2008) Stabilization of alpha-chymotrypsin upon PEGylation correlates with reduced structural dynamics. Biotechnol Bioeng 101:1142-1149.
22. Estrada J, Bernado P, Blackledge M, Sancho J (2009) ProtSA: a web application for calculating sequence specific protein solvent accessibilities in the unfolded ensemble. BMC Bioinformatics 10:104.
23. Gordon JC, Myers JB, Folta T, Shoja V, Heath LS, Onufriev A (2005) H++: a server for estimating pKas and adding missing hydrogens to macromolecules. Nucleic Acids Res 33:W368-W371.
24. Fojta M, Kubicarova T, Vojtesek B, Palecek E (1999) Effect of p53 protein redox states on binding to super-coiled and linear DNA. J Biol Chem 274:25749-25755.
25. Hainaut P, Milner J (1993) Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res 53:4469-4473.
26. Rainwater R, Parks D, Anderson ME, Tegtmeyer P, Mann K (1995) Role of cysteine residues in regulation of p53 function. Mol Cell Biol 15:3892-3903.
27. Stoner CS, Pearson GD, Koc A, Merwin JR, Lopez NI, Merrill GF (2009) Effect of thioredoxin deletion and p53 cysteine replacement on human p53 activity in wild-type and thioredoxin reductase null yeast. Biochemistry 48:9156-9169.
28. Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, Honig B, Shakked Z (2010) Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol 17:423-429.
29. Na HK, Surh YJ (2006) Transcriptional regulation via cysteine thiol modification: a novel molecular strategy for chemoprevention and cytoprotection. Mol Carcinog 45:368-380.
30. Veprintsev DB, Fersht AR (2008) Algorithm for prediction of tumour suppressor p53 affinity for binding sites in DNA. Nucleic Acids Res 36:1589-1598.
31. Joerger AC, Allen MD, Fersht AR (2004) Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 279:1291-1296.
32. Nikolova PV, Henckel J, Lane DP, Fersht AR (1998) Semirational design of active tumor suppressor p53 DNA binding domain with enhanced stability. Proc Natl Acad Sci USA 95:14675-14680. (Pubitemid 29003689)
33. Hajduk PJ, Dinges J, Miknis GF, Merlock M, Middleton T, Kempf DJ, Egan DA, Walter KA, Robins TS, Shuker SB, Holzman TF, Fesik SW (1997) NMR-based discovery of lead inhibitors that block DNA binding of the human papillomavirus E2 protein. J Med Chem 40:3144-3150.
34. Leslie AG (1999) Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 55:1696-1702.
35. Evans P (2006) Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62:72-82.
36. Adams PD, Grosse-Kunstleve RW, Hung LW, Ioerger TR, McCoy AJ, Moriarty NW, Read RJ, Sacchettini JC, Sauter NK, Terwilliger TC (2002) PHENIX: building new software for automated crystallographic structure determination. Acta Cryst D58:1948-1954.
37. Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501.
38. Friedler A, Veprintsev DB, Hansson LO, Fersht AR (2003) Kinetic instability of p53 core domain mutants: implications for rescue by small molecules. J Biol Chem 278:24108-24112.